Skip to content
SPACListing
CompletedOTC

ZyVersa Therapeutics, Inc.ZVSA

Class A ZVSACIK 0001859007

Cash in trust

$78.9M

$78,911,942

Trust per share

$10.52

Redemption value

IPO

Dec 2021

$18.1M raised

Combination deadline

—

Not disclosed

Filings on record

318

Latest Jul 16, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
Jul 21, 2022
Closed
Dec 13, 2022

Overview

ZyVersa Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001859007. It completed its initial public offering in Dec 2021, raising $18.1M in gross proceeds and listing on OTC. Class A shares trade under the ticker ZVSA on OTC. The vehicle is sponsored by Larkspur Health through Larkspur Health LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.

“we intend to focus our search on companies in the biotechnology sector in the United States.”
The mandate, as stated in the IPO prospectus
HealthcareNorth America

Reading the filings

Arithmetic on what ZyVersa Therapeutics, Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $10.52 per public share, 5.2% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.

  • Underwriting

    A.G.P./Alliance Global led the offering. It has been named on 18 SPAC IPOs, book-running 18 of them, and 83.3% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

261302021-052026-07

318 filings in all. 3 in the last three months, against a busiest month of 26.

News on ZyVersa Therapeutics, Inc.

Last 90 days

Nothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.

SEC filing history

Free tier: filings older than 24 hours
  • 8-K

    Other events

    Item 8.01 · Accession 0001493152-26-033565

    Jul 16, 2026

    3mo ago

    View on EDGAR ↗
  • 8-K

    Other events

    Items 5.02, 8.01 · Accession 0001493152-26-032851

    Jul 10, 2026

    3mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001493152-26-022759

    May 13, 2026

    5mo ago

    View on EDGAR ↗
  • 10-K

    Annual report

    Accession 0001493152-26-014271

    Mar 31, 2026

    7mo ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 9.01 · Accession 0001493152-26-008994

    Mar 5, 2026

    8mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Item 5.02 · Accession 0001493152-25-025966

    Dec 3, 2025

    11mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Items 2.02, 9.01 · Accession 0001493152-25-024273

    Nov 19, 2025

    11mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001493152-25-024263

    Nov 19, 2025

    11mo ago

    View on EDGAR ↗
  • NT 10-Q

    Late quarterly report notification

    Accession 0001493152-25-023612

    Nov 14, 2025

    11mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Item 5.02 · Accession 0001493152-25-018156

    Oct 15, 2025

    1y ago

    View on EDGAR ↗
  • 25-NSE

    Notification of delisting

    Accession 0001354457-25-000988

    Oct 6, 2025

    1y ago

    View on EDGAR ↗
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Item 3.01 · Accession 0001493152-25-013968

    Sep 18, 2025

    1y ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001172661-25-003603

    Aug 15, 2025

    1y ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001641172-25-023342

    Aug 13, 2025

    1y ago

    View on EDGAR ↗
  • EFFECT

    Notice of effectiveness

    Accession 9999999995-25-002497

    Aug 7, 2025

    1y ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001641172-25-022236

    Aug 5, 2025

    1y ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001641172-25-021954

    Aug 1, 2025

    1y ago

    View on EDGAR ↗
  • S-1/A

    S-1/A

    Accession 0001641172-25-021952

    Aug 1, 2025

    1y ago

    View on EDGAR ↗
  • UPLOAD

    SEC staff comment letter

    Accession 0000000000-25-008006

    Jul 30, 2025

    1y ago

    View on EDGAR ↗
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001641172-25-021100

    Jul 28, 2025

    1y ago

    View on EDGAR ↗
  • S-1/A

    S-1/A

    Accession 0001641172-25-020253

    Jul 18, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019858

    Jul 16, 2025

    1y ago

    View on EDGAR ↗
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Items 3.01, 9.01 · Accession 0001641172-25-019856

    Jul 16, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019724

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019725

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019723

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019729

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019726

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019727

    Jul 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001641172-25-019728

    Jul 15, 2025

    1y ago

    View on EDGAR ↗

Pro

Track ZVSA without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

ZyVersa Therapeutics, Inc.: questions answered

What is ZyVersa Therapeutics, Inc. (ZVSA)?

ZyVersa Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001859007. It completed its initial public offering in Dec 2021, raising $18.1M in gross proceeds and listing on OTC. Class A shares trade under the ticker ZVSA on OTC. The vehicle is sponsored by Larkspur Health through Larkspur Health LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.

How much does ZyVersa Therapeutics, Inc. hold in trust?

Approximately $78,911,942, or about $10.52 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must ZyVersa Therapeutics, Inc. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if ZyVersa Therapeutics, Inc. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in ZyVersa Therapeutics, Inc., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.52 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does ZyVersa Therapeutics, Inc. trade under?

Class A shares trade as ZVSA on OTC. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for ZyVersa Therapeutics, Inc.?

No, and the gap between them is the whole trade. Trust per share is a disclosed, contractual figure of $10.52, being what a redeeming holder receives. The market price is whatever the shares change hands at: most recently $0.00, a spread to the redemption value. Quotes on this site are delayed and indicative; confirm on your own venue before trading.

Who sponsors ZyVersa Therapeutics, Inc., and what is their track record?

Larkspur Health LLC is the sponsor entity, part of the Larkspur Health franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Daniel J. O’Connor.

Which banks underwrote the ZyVersa Therapeutics, Inc. IPO?

A.G.P./Alliance Global, Benchmark Company, Brookline. A.G.P./Alliance Global and Benchmark Company were credited as book-running managers on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is ZyVersa Therapeutics, Inc. tradeable, and where?

Yes. ZVSA returned a live quote of $0.00 on OTC. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is ZyVersa Therapeutics, Inc. a good investment?

That is not a question this site answers. ZyVersa Therapeutics, Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this ZyVersa Therapeutics, Inc. data come from?

Filings ZyVersa Therapeutics, Inc. submitted to the SEC under CIK 0001859007: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Nov 1, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.